Skip to Content
Merck
CN
  • Coupling primary and stem cell-derived cardiomyocytes in an in vitro model of cardiac cell therapy.

Coupling primary and stem cell-derived cardiomyocytes in an in vitro model of cardiac cell therapy.

The Journal of cell biology (2016-02-10)
Yvonne Aratyn-Schaus, Francesco S Pasqualini, Hongyan Yuan, Megan L McCain, George J C Ye, Sean P Sheehy, Patrick H Campbell, Kevin Kit Parker
ABSTRACT

The efficacy of cardiac cell therapy depends on the integration of existing and newly formed cardiomyocytes. Here, we developed a minimal in vitro model of this interface by engineering two cell microtissues (μtissues) containing mouse cardiomyocytes, representing spared myocardium after injury, and cardiomyocytes generated from embryonic and induced pluripotent stem cells, to model newly formed cells. We demonstrated that weaker stem cell-derived myocytes coupled with stronger myocytes to support synchronous contraction, but this arrangement required focal adhesion-like structures near the cell-cell junction that degrade force transmission between cells. Moreover, we developed a computational model of μtissue mechanics to demonstrate that a reduction in isometric tension is sufficient to impair force transmission across the cell-cell boundary. Together, our in vitro and in silico results suggest that mechanotransductive mechanisms may contribute to the modest functional benefits observed in cell-therapy studies by regulating the amount of contractile force effectively transmitted at the junction between newly formed and spared myocytes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
4-Nitro-3-(trifluoromethyl)phenol, 99% (GC)
Sigma-Aldrich
Poly(dimethylsiloxane), viscosity 1.0 cSt (25 °C)
Sigma-Aldrich
Anti-β-Catenin antibody produced in rabbit, whole antiserum